Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.DermaGenoma Introduces PsoriasisDX Genetic Test In Europe
DermaGenoma said that the CE marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives. The PsoriasisDX Genetic Test
DermaGenoma said that the CE marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives. The PsoriasisDX Genetic Test
Under a manufacturing agreement signed between Daiichi Sankyo and Sanofi-Aventis in 1993, Sanofi-Aventis has launched Levofloxacin in more than 90 countries as Tavanic. Daiichi Sankyo and Sanofi-Aventis have
Eli Lilly said that the acquisition, initiated on July 2, 2010, has received the approval of Alnara stockholders and clearance under the Hart-Scott-Rodino Antitrust Improvements Act. As per
Prolor said that hGH is its proprietary biobetter version of human growth hormone. The Phase II study was commenced to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic properties
The project is being undertaken in collaboration with Sam Gunderson and Rafal Goraczniak at SilaGene (Hillsborough, NJ), a newly formed biotechnology company working on U1 Adapter therapeutics. IDT
As per the contract, Astellas is expected to pay EUR25m in three tranches as the steps of transfer of the rights are expected to be concluded over the
SPX said that the transaction includes all Anhydro’s business units with the exception of its Danish Filter business, Simatek, and its German, UK and US operations, as well
The chemical pharmaceutical factory with latest technologies is said to have good manufacturing practice (GMP), good storage practice (GSP) and good laboratory practice (GLP). VCP is set to
Mr King is expected to look after clinical operations and site management for Chimerix and Dr Mommeja-Marin will oversee clinical strategy and study design. Both will report to
Ampio Pharma claimed that Optina is a repurposed oral drug with an established human safety profile. Pre-clinical studies have shown the potential for Optina to reduce diabetic macular